uniQure N.V. cotiza a 21.84 USD y tiene una capitalización bursátil de $1.5B. En los últimos 12 meses ha facturado $18M con un margen de flujo de caja libre del -1108.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, whic…
| Periodo | 2026-11 | 2026-07 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.07 | $-0.73 | $-0.47 |
| Estimado | $-0.83 | $-0.71 | $-0.75 | $-0.78 |
| Sorpresa | — | -50.7% | +2.7% | +39.7% |
| Métrica | QURE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 89.5% | 57.0% | +32.5% |
| Operating Margin | -1151.4% | -38.6% | -1112.8% |
| Net Margin | -1236.0% | -33.6% | -1202.4% |
| FCF Margin | -1108.2% | -13.9% | -1094.4% |
| ROE | -100.0% | -40.4% | -59.6% |
| ROA | -24.1% | -32.0% | +7.9% |
| Current Ratio | 10.43 | 2.84 | +7.59 |
| Debt / Equity | 0.36 | 0.28 | +0.08 |